The test uses fluid taken from patients to identify this complex, which may be associated with inflammation due to cartilage and spinal disc damage or degeneration. The patent includes diagnostic kit claims for detecting the Fibronectin and Aggrecan Complex and can be used to pinpoint the source of musculoskeletal pain.
More Articles on Pain Management:
8 Benchmarks for Low Back Pain Injections
Maintaining Quality at Pain Centers: Q&A With Dr. Edward Tavel of Pain Specialists of Charleston
Kentucky Society for Interventional Pain Physicians Tackles Opioid Prescribing
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.